content: <PAGE>   1
  
  
                  As filed with the Securities and Exchange Commission
                                    on July 19, 1996
  
  
  
  ================================================================================
                                                                             
                         SECURITIES AND EXCHANGE COMMISSION
                               Washington, D.C. 20549
  
                                      FORM S-8
  
                            REGISTRATION STATEMENT UNDER
                             THE SECURITIES ACT OF 1933
  
                        IMMULOGIC PHARMACEUTICAL CORPORATION
               (Exact name of registrant as specified in its charter)
  
                      DELAWARE                               33-3397957
           (State or other jurisdiction of                (I.R.S. Employer
            incorporation or organization)               Identification No.)
  
                     610 LINCOLN STREET, WALTHAM, MASSACHUSETTS 02154  
                (Address of Principal Executive Offices)     (Zip Code)
  
                               1996 STOCK OPTION PLAN
                              (Full title of the plan)
  
                                  RICHARD N. SMALL
                     VICE PRESIDENT AND CHIEF FINANCIAL OFFICER
                        IMMULOGIC PHARMACEUTICAL CORPORATION
                                 610 LINCOLN STREET
                            WALTHAM, MASSACHUSETTS 02154
                       (Name and address of agent for service)
  
                                   (617) 466-6000
            (Telephone number, including area code, of agent for service)
  
  ================================================================================
  
                           CALCULATION OF REGISTRATION FEE                   
  
                                  Proposed     Proposed
  Title of                        maximum      maximum
  securities       Amount         offering     aggregate      Amount of
  to be            to be          price        offering       registration
  registered       registered     per share    price          fee
  - ----------       ----------     ---------    ---------      ------------
  
  Common Stock,     500,000       $7.00(1)     $3,500,000(1)  $1,207.00
  $.01 par          shares
  value
  
  - --------------------------------------------------------------------------------
  (1)  Estimated solely for the purpose of calculating the registration fee, and
       based upon the average of the high and low prices of the Common Stock on
       the Nasdaq National Market on July 17, 1996 in accordance with Rules
       457(c) and 457(h) of the Securities Act of 1933.
  
  ================================================================================
  
  
  
  
                                 Page 1 of 11 pages
                           Exhibit Index begins on page 8
  
  <PAGE>   2
  
  
  
  
  
  PART I.  INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
  
       The information required by Part I is included in documents sent or given
  to participants in the 1996 Stock Option Plan of ImmuLogic Pharmaceutical
  Corporation, a Delaware corporation (the "Registrant"), pursuant to Rule
  428(b)(1).
  
  PART II. INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
  
       Item 3. Incorporation of Documents by Reference.
               ---------------------------------------
  
       The Registrant is subject to the informational and reporting requirements
  of Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as
  amended (the "Exchange Act"), and in accordance therewith files reports, proxy
  statements and other information with the Securities and Exchange Commission.
  The following documents, which are filed with the Securities and Exchange
  Commission, are incorporated in this Prospectus by reference:
  
            (1) The Registrant's latest annual report filed pursuant to Section
       13(a) or 15(d) of the Exchange Act, or the latest prospectus filed pursuant
       to Rule 424(b) under the Securities Act of 1933, as amended (the
       "Securities Act"), that contains audited financial statements for the
       Registrant's latest fiscal year for which such statements have been filed.
  
            (2) All other reports filed pursuant to Section 13(a) or 15(d) of the
       Exchange Act since the end of the fiscal year covered by the document
       referred to in (1) above.
  
            (3) The description of the Common Stock, par value $.01 per share
       ("Common Stock"), contained in a registration statement filed under the
       Exchange Act, including any amendment or report filed for the purpose of
       updating such description.
  
       All documents subsequently filed by the Registrant pursuant to Sections
  13(a), 13(c), 14, and 15(d) of the Exchange Act, prior to the filing of a
  post-effective amendment which indicates that all shares of Common Stock offered
  hereby have been sold or which deregisters all shares of Common Stock then
  remaining unsold, shall be deemed to be incorporated by reference herein and to
  be part hereof from the date of the filing of such documents.
  
       Item 4. Description of Securities.
               -------------------------
  
       Not applicable.
  
  
  
  
  
  
                                         -2-
  <PAGE>   3
  
  
  
  
  
       Item 5. Interests of Named Experts and Counsel.
               --------------------------------------
  
       Not applicable.
  
       Item 6. Indemnification of Directors and Officers.
               -----------------------------------------
  
       Section 145 of the Delaware General Corporation Law provides that a
  corporation may indemnify any person who was or is a party or is threatened to
  be made a party to any threatened, pending or completed action or proceeding,
  whether civil, criminal, administrative or investigative, by reason of the fact
  that he is or was a director, officer, employee or agent of the corporation or
  is or was serving at its request in such capacity in another corporation or
  business association, against expenses (including attorneys' fees), judgments,
  fines and amounts paid in settlement actually and reasonably incurred by him in
  connection with such action, suit or proceeding if he acted in good faith and in
  a manner he reasonably believed to be in or not opposed to the best interests of
  the corporation, and, with respect to any criminal action or proceeding, had no
  reasonable cause to believe his conduct was unlawful.
  
       Section 102(b)(7) of the Delaware General Corporation Law permits a
  corporation to provide in its certificate of incorporation that a director of
  the corporation shall not be personally liable to the corporation or its
  stockholders for monetary damages for breach of fiduciary duty as a director,
  except for liability (i) for any breach of the director's duty of loyalty to the
  corporation or its stockholders, (ii) for acts or omissions not in good faith or
  which involve intentional misconduct or a knowing violation of law, (iii) under
  Section 174 of the Delaware General Corporation Law, or (iv) for any transaction
  from which the director derived an improper personal benefit.
  
       Article EIGHTH of the Registrant's Restated Certificate of Incorporation,
  as amended, requires the Registrant to indemnify each person who is or was or
  has agreed to be a director or officer of the Registrant against expenses
  (including attorneys' fees), judgments, fines and amounts paid in settlement to
  the maximum extent permitted from time to time under the Delaware General
  Corporation Law, as amended. In addition, Article NINTH provides that no
  director of the Registrant shall be liable for monetary damages for any breach
  of fiduciary duty, except to the extent that the Delaware General Corporation
  Law prohibits the elimination or limitation of liability of directors for breach
  of fiduciary duty.
  
       Item 7. Exemption from Registration Claimed.
               -----------------------------------
  
       Not applicable.
  
  
  
  
                                         -3-
  <PAGE>   4
  
  
  
  
  
       Item 8. Exhibits.
               --------
  
       The Exhibit Index immediately preceding the exhibits is incorporated herein
  by reference.
  
       Item 9. Undertakings.
               ------------
  
       1.   The Registrant hereby undertakes:
  
            (a) To file, during any period in which offers or sales are being
       made, a post-effective amendment to this registration statement:
  
            (i) To include any prospectus required by Section 10(a)(3) of the
       Securities Act;
  
           (ii) To reflect in the prospectus any facts or events arising after
       the effective date of the registration statement (or the most recent
       post-effective amendment thereof) which, individually or in the aggregate,
       represent a fundamental change in the information set forth in the
       registration statement; and
  
          (iii) To include any material information with respect to the plan of
       distribution not previously disclosed in the registration statement or any
       material change to such information in the registration statement;
  
       PROVIDED, HOWEVER that paragraphs (i) and (ii) do not apply if the
       registration statement is on Form S-3 or Form S-8, and the information
       required to be included in a post-effective amendment by those paragraphs
       is contained in periodic reports filed by the Registrant pursuant to
       Section 13 or Section 15(d) of the Exchange Act that are incorporated by
       reference in the registration statement.
  
            (b) That, for the purpose of determining any liability under the
       Securities Act, each such post-effective amendment shall be deemed to be a
       new registration statement relating to the securities offered therein, and
       the offering of such securities at that time shall be deemed to be the
       initial bona fide offering thereof.
  
            (c) To remove from registration by means of a post-effective amendment
       any of the securities being registered which remain unsold at the
       termination of the offering.
  
       2. The Registrant hereby undertakes that, for purposes of determining any
  liability under the Securities Act, each filing of the Registrant's annual
  report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and,
  where applicable, each
  
  
  
                                         -4-
  <PAGE>   5
  
  
  
  
  
  filing of an employee benefit plan's annual report pursuant to Section 15(d) of
  the Exchange Act) that is incorporated by reference in the registration
  statement shall be deemed to be a new registration statement relating to the
  securities offered therein, and the offering of such securities at that time
  shall be deemed to be in the initial bona fide offering thereof.
  
       3. Insofar as indemnification for liabilities arising under the Securities
  Act may be permitted to directors, officers and controlling persons of the
  Registrant pursuant to the foregoing provisions, or otherwise, the Registrant
  has been advised that in the opinion of the Securities and Exchange Commission
  such indemnification is against public policy as expressed in the Securities Act
  and is, therefore, unenforceable. In the event that a claim for indemnification
  against such liabilities (other than the payment by the Registrant of expenses
  incurred or paid by a director, officer or controlling person of the Registrant
  in the successful defense of any action, suit or proceeding) is asserted by such
  director, officer or controlling person in connection with the securities being
  registered, the Registrant will, unless in the opinion of its counsel the matter
  has been settled by controlling precedent, submit to a court of appropriate
  jurisdiction the question whether such indemnification by it is against public
  policy as expressed in the Securities Act and will be governed by the final
  adjudication of such issue.
  
  
  
  
  
  
                                         -5-
  <PAGE>   6
  
  
  
  
  
  
                                     SIGNATURES
  
       Pursuant to the requirements of the Securities Act, the Registrant
  certifies that it has reasonable grounds to believe that it meets all of the
  requirements for filing on Form S-8 and has duly caused this Registration
  Statement to be signed on its behalf by the undersigned, thereunto duly
  authorized, in the City of Waltham, Commonwealth of Massachusetts on the 18th
  day of July, 1996.
  
  
                                         IMMULOGIC PHARMACEUTICAL CORPORATION
  
  
  
                                         By: /s/ Robert J. Gerety
                                            -----------------------------------
                                            Robert J. Gerety, M.D. Ph.D.
                                            President and
                                            Chief Executive Officer
  
  
  
                                  POWER OF ATTORNEY
  
       We, the undersigned officers and directors of ImmuLogic Pharmaceutical
  Corporation hereby severally constitute Robert J. Gerety, Richard N. Small and
  Stacey L. Channing, and each of them singly, our true and lawful attorneys with
  full power to them, and each of them singly, to sign for us and in our names in
  the capacities indicated below, the Registration Statement on Form S-8 filed
  herewith and any and all subsequent amendments to said Registration Statement,
  and generally to do all such things in our names and behalf in our capacities as
  officers and directors to enable ImmuLogic Pharmaceutical Corporation to comply
  with all requirements of the Securities and Exchange Commission, hereby
  ratifying and confirming our signatures as they may be signed by said attorneys,
  or any of them, to said Registration Statement and any and all amendments
  thereto.
  
  
  
  
  
  
                                         -6-
  <PAGE>   7
  
  
  
  
  
  
  
       Pursuant to the requirements of the Securities Act, this Registration
  Statement has been signed below by the following persons in the capacities and
  on the date indicated.
  
  Signature                            Title                    Date
  - ---------                            -----                    ----
  
  
  /s/ Robert J. Gerety             President, Chief        )
  - ------------------------------   Executive Officer       )
  Robert J. Gerety, M.D., Ph.D.    and Director            )
                                   (Principal Executive    )
                                   Officer)                )
                                                           )
  /s/ Richard N. Small             Vice President,         )
  - ------------------------------   Chief Financial Officer )
  Richard N. Small                 (Principal Financial    )
                                   and Accounting Officer  )
                                                           )
                                                           )
  /s/ Malcolm L. Gefter            Director                )
  - ------------------------------                           )
  Malcolm L. Gefter, Ph.D.                                 )
                                                           )
                                                           )
                                                           )
  /s/ Alan J. Dalby                Director                )
  - ------------------------------                           )               
  Alan J. Dalby                                            ) July 18, 1996 
                                                           )
                                                           )
                                                           )
  /s/ M Howard Jacobson            Director                )
  - ------------------------------                           )
  M Howard Jacobson                                        )
                                                           )
                                                           )
                                                           )
  /s/ Kenneth L. Melmon            Director                )
  - ------------------------------                           ) 
  Kenneth L. Melmon, M.D.                                  ) 
                                                           ) 
                                                           )
                                                           )
  /s/ Larry Soll                   Director                )
  - ------------------------------                           )
  Larry Soll, Ph.D.                                        )
                                                           )
                                                           )
                                                           )
  
  
  
  
  
                                        -7-
  <PAGE>   8
  
  
  
  
  
  
                                    EXHIBIT INDEX
                                    -------------
  
  
  Exhibit
  Number       Description                                         
  - -------      -----------                                         
                                                                   
   4.1 *       By-Laws of the Registrant                           
                                                                   
   4.2 *       Specimen Certificate of Common Stock of             
               the Registrant                                      
                                                                   
   4.3 **      Rights Agreement, dated as of July 11, 1995,        
               between the Registrant and the First National       
               Bank of Boston, as Rights Agent.                    
                                                                   
   5           Opinion of Hale and Dorr                            
                                                                   
  23.1         Consent of Hale and Dorr (included in Exhibit 5)    
                                                                   
  23.2         Consent of Coopers & Lybrand L.L.P.                 
                                                                   
  24           Power of Attorney (included in the signature pages  
               of this Registration Statement)                     
  
  
       ------------------------------
       *    Incorporated herein by reference from the Registrant's Registration 
            Statement on Form S-1 (File No. 33-39592).
  
       **   Incorporated herein by reference from the Registrant's Current Report
            on Form 8-K dated July 11, 1995.  
  
  
  
  
                                         -8-
metadata_documents: [{"type": "S-8", "sequence": "1", "description": "IMMULOGIC PHARMACEUTICALS 1996 STOCK OPTION PLAN", "secsgml_size_bytes": 18385}]
metadata_filer: {"company-data": {"conformed-name": "IMMULOGIC PHARMACEUTICAL CORP /DE", "cik": "0000873731", "assigned-sic": "2834", "irs-number": "133397957", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-08425", "film-number": "96596683"}, "business-address": {"street1": "610 LINCOLN ST", "city": "WALTHAM", "state": "MA", "zip": "02154", "phone": "6174666000"}, "mail-address": {"street1": "610 LINCOLN ST", "city": "WALTHAM", "state": "MA", "zip": "02154"}}
text: 1
  
                  As filed with the Securities and Exchange Commission
                                    on July 19, 1996
  
  ================================================================================
                                                                             
                         SECURITIES AND EXCHANGE COMMISSION
                               Washington, D.C. 20549
  
                                      FORM S-8
  
                            REGISTRATION STATEMENT UNDER
                             THE SECURITIES ACT OF 1933
  
                        IMMULOGIC PHARMACEUTICAL CORPORATION
               (Exact name of registrant as specified in its charter)
  
                      DELAWARE                               33-3397957
           (State or other jurisdiction of                (I.R.S. Employer
            incorporation or organization)               Identification No.)
  
                     610 LINCOLN STREET, WALTHAM, MASSACHUSETTS 02154  
                (Address of Principal Executive Offices)     (Zip Code)
  
                               1996 STOCK OPTION PLAN
                              (Full title of the plan)
  
                                  RICHARD N. SMALL
                     VICE PRESIDENT AND CHIEF FINANCIAL OFFICER
                        IMMULOGIC PHARMACEUTICAL CORPORATION
                                 610 LINCOLN STREET
                            WALTHAM, MASSACHUSETTS 02154
                       (Name and address of agent for service)
  
                                   (617) 466-6000
            (Telephone number, including area code, of agent for service)
  
  ================================================================================
  
                           CALCULATION OF REGISTRATION FEE                   
  
                                  Proposed     Proposed
  Title of                        maximum      maximum
  securities       Amount         offering     aggregate      Amount of
  to be            to be          price        offering       registration
  registered       registered     per share    price          fee
  - ----------       ----------     ---------    ---------      ------------
  
  Common Stock,     500,000       $7.00(1)     $3,500,000(1)  $1,207.00
  $.01 par          shares
  value
  
  - --------------------------------------------------------------------------------
  (1)  Estimated solely for the purpose of calculating the registration fee, and
       based upon the average of the high and low prices of the Common Stock on
       the Nasdaq National Market on July 17, 1996 in accordance with Rules
       457(c) and 457(h) of the Securities Act of 1933.
  
  ================================================================================
  
                                 Page 1 of 11 pages
                           Exhibit Index begins on page 8
  2
  
  PART I.  INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
  
       The information required by Part I is included in documents sent or given
  to participants in the 1996 Stock Option Plan of ImmuLogic Pharmaceutical
  Corporation, a Delaware corporation (the "Registrant"), pursuant to Rule
  428(b)(1).
  
  PART II. INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
  
       Item 3. Incorporation of Documents by Reference.
               ---------------------------------------
  
       The Registrant is subject to the informational and reporting requirements
  of Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as
  amended (the "Exchange Act"), and in accordance therewith files reports, proxy
  statements and other information with the Securities and Exchange Commission.
  The following documents, which are filed with the Securities and Exchange
  Commission, are incorporated in this Prospectus by reference:
  
            (1) The Registrant's latest annual report filed pursuant to Section
       13(a) or 15(d) of the Exchange Act, or the latest prospectus filed pursuant
       to Rule 424(b) under the Securities Act of 1933, as amended (the
       "Securities Act"), that contains audited financial statements for the
       Registrant's latest fiscal year for which such statements have been filed.
  
            (2) All other reports filed pursuant to Section 13(a) or 15(d) of the
       Exchange Act since the end of the fiscal year covered by the document
       referred to in (1) above.
  
            (3) The description of the Common Stock, par value $.01 per share
       ("Common Stock"), contained in a registration statement filed under the
       Exchange Act, including any amendment or report filed for the purpose of
       updating such description.
  
       All documents subsequently filed by the Registrant pursuant to Sections
  13(a), 13(c), 14, and 15(d) of the Exchange Act, prior to the filing of a
  post-effective amendment which indicates that all shares of Common Stock offered
  hereby have been sold or which deregisters all shares of Common Stock then
  remaining unsold, shall be deemed to be incorporated by reference herein and to
  be part hereof from the date of the filing of such documents.
  
       Item 4. Description of Securities.
               -------------------------
  
       Not applicable.
  
                                         -2-
  3
  
       Item 5. Interests of Named Experts and Counsel.
               --------------------------------------
  
       Not applicable.
  
       Item 6. Indemnification of Directors and Officers.
               -----------------------------------------
  
       Section 145 of the Delaware General Corporation Law provides that a
  corporation may indemnify any person who was or is a party or is threatened to
  be made a party to any threatened, pending or completed action or proceeding,
  whether civil, criminal, administrative or investigative, by reason of the fact
  that he is or was a director, officer, employee or agent of the corporation or
  is or was serving at its request in such capacity in another corporation or
  business association, against expenses (including attorneys' fees), judgments,
  fines and amounts paid in settlement actually and reasonably incurred by him in
  connection with such action, suit or proceeding if he acted in good faith and in
  a manner he reasonably believed to be in or not opposed to the best interests of
  the corporation, and, with respect to any criminal action or proceeding, had no
  reasonable cause to believe his conduct was unlawful.
  
       Section 102(b)(7) of the Delaware General Corporation Law permits a
  corporation to provide in its certificate of incorporation that a director of
  the corporation shall not be personally liable to the corporation or its
  stockholders for monetary damages for breach of fiduciary duty as a director,
  except for liability (i) for any breach of the director's duty of loyalty to the
  corporation or its stockholders, (ii) for acts or omissions not in good faith or
  which involve intentional misconduct or a knowing violation of law, (iii) under
  Section 174 of the Delaware General Corporation Law, or (iv) for any transaction
  from which the director derived an improper personal benefit.
  
       Article EIGHTH of the Registrant's Restated Certificate of Incorporation,
  as amended, requires the Registrant to indemnify each person who is or was or
  has agreed to be a director or officer of the Registrant against expenses
  (including attorneys' fees), judgments, fines and amounts paid in settlement to
  the maximum extent permitted from time to time under the Delaware General
  Corporation Law, as amended. In addition, Article NINTH provides that no
  director of the Registrant shall be liable for monetary damages for any breach
  of fiduciary duty, except to the extent that the Delaware General Corporation
  Law prohibits the elimination or limitation of liability of directors for breach
  of fiduciary duty.
  
       Item 7. Exemption from Registration Claimed.
               -----------------------------------
  
       Not applicable.
  
                                         -3-
  4
  
       Item 8. Exhibits.
               --------
  
       The Exhibit Index immediately preceding the exhibits is incorporated herein
  by reference.
  
       Item 9. Undertakings.
               ------------
  
       1.   The Registrant hereby undertakes:
  
            (a) To file, during any period in which offers or sales are being
       made, a post-effective amendment to this registration statement:
  
            (i) To include any prospectus required by Section 10(a)(3) of the
       Securities Act;
  
           (ii) To reflect in the prospectus any facts or events arising after
       the effective date of the registration statement (or the most recent
       post-effective amendment thereof) which, individually or in the aggregate,
       represent a fundamental change in the information set forth in the
       registration statement; and
  
          (iii) To include any material information with respect to the plan of
       distribution not previously disclosed in the registration statement or any
       material change to such information in the registration statement;
  
       PROVIDED, HOWEVER that paragraphs (i) and (ii) do not apply if the
       registration statement is on Form S-3 or Form S-8, and the information
       required to be included in a post-effective amendment by those paragraphs
       is contained in periodic reports filed by the Registrant pursuant to
       Section 13 or Section 15(d) of the Exchange Act that are incorporated by
       reference in the registration statement.
  
            (b) That, for the purpose of determining any liability under the
       Securities Act, each such post-effective amendment shall be deemed to be a
       new registration statement relating to the securities offered therein, and
       the offering of such securities at that time shall be deemed to be the
       initial bona fide offering thereof.
  
            (c) To remove from registration by means of a post-effective amendment
       any of the securities being registered which remain unsold at the
       termination of the offering.
  
       2. The Registrant hereby undertakes that, for purposes of determining any
  liability under the Securities Act, each filing of the Registrant's annual
  report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and,
  where applicable, each
  
                                         -4-
  5
  
  filing of an employee benefit plan's annual report pursuant to Section 15(d) of
  the Exchange Act) that is incorporated by reference in the registration
  statement shall be deemed to be a new registration statement relating to the
  securities offered therein, and the offering of such securities at that time
  shall be deemed to be in the initial bona fide offering thereof.
  
       3. Insofar as indemnification for liabilities arising under the Securities
  Act may be permitted to directors, officers and controlling persons of the
  Registrant pursuant to the foregoing provisions, or otherwise, the Registrant
  has been advised that in the opinion of the Securities and Exchange Commission
  such indemnification is against public policy as expressed in the Securities Act
  and is, therefore, unenforceable. In the event that a claim for indemnification
  against such liabilities (other than the payment by the Registrant of expenses
  incurred or paid by a director, officer or controlling person of the Registrant
  in the successful defense of any action, suit or proceeding) is asserted by such
  director, officer or controlling person in connection with the securities being
  registered, the Registrant will, unless in the opinion of its counsel the matter
  has been settled by controlling precedent, submit to a court of appropriate
  jurisdiction the question whether such indemnification by it is against public
  policy as expressed in the Securities Act and will be governed by the final
  adjudication of such issue.
  
                                         -5-
  6
  
                                     SIGNATURES
  
       Pursuant to the requirements of the Securities Act, the Registrant
  certifies that it has reasonable grounds to believe that it meets all of the
  requirements for filing on Form S-8 and has duly caused this Registration
  Statement to be signed on its behalf by the undersigned, thereunto duly
  authorized, in the City of Waltham, Commonwealth of Massachusetts on the 18th
  day of July, 1996.
  
                                         IMMULOGIC PHARMACEUTICAL CORPORATION
  
                                         By: /s/ Robert J. Gerety
                                            -----------------------------------
                                            Robert J. Gerety, M.D. Ph.D.
                                            President and
                                            Chief Executive Officer
  
                                  POWER OF ATTORNEY
  
       We, the undersigned officers and directors of ImmuLogic Pharmaceutical
  Corporation hereby severally constitute Robert J. Gerety, Richard N. Small and
  Stacey L. Channing, and each of them singly, our true and lawful attorneys with
  full power to them, and each of them singly, to sign for us and in our names in
  the capacities indicated below, the Registration Statement on Form S-8 filed
  herewith and any and all subsequent amendments to said Registration Statement,
  and generally to do all such things in our names and behalf in our capacities as
  officers and directors to enable ImmuLogic Pharmaceutical Corporation to comply
  with all requirements of the Securities and Exchange Commission, hereby
  ratifying and confirming our signatures as they may be signed by said attorneys,
  or any of them, to said Registration Statement and any and all amendments
  thereto.
  
                                         -6-
  7
  
       Pursuant to the requirements of the Securities Act, this Registration
  Statement has been signed below by the following persons in the capacities and
  on the date indicated.
  
  Signature                            Title                    Date
  - ---------                            -----                    ----
  
  /s/ Robert J. Gerety             President, Chief        )
  - ------------------------------   Executive Officer       )
  Robert J. Gerety, M.D., Ph.D.    and Director            )
                                   (Principal Executive    )
                                   Officer)                )
                                                           )
  /s/ Richard N. Small             Vice President,         )
  - ------------------------------   Chief Financial Officer )
  Richard N. Small                 (Principal Financial    )
                                   and Accounting Officer  )
                                                           )
                                                           )
  /s/ Malcolm L. Gefter            Director                )
  - ------------------------------                           )
  Malcolm L. Gefter, Ph.D.                                 )
                                                           )
                                                           )
                                                           )
  /s/ Alan J. Dalby                Director                )
  - ------------------------------                           )               
  Alan J. Dalby                                            ) July 18, 1996 
                                                           )
                                                           )
                                                           )
  /s/ M Howard Jacobson            Director                )
  - ------------------------------                           )
  M Howard Jacobson                                        )
                                                           )
                                                           )
                                                           )
  /s/ Kenneth L. Melmon            Director                )
  - ------------------------------                           ) 
  Kenneth L. Melmon, M.D.                                  ) 
                                                           ) 
                                                           )
                                                           )
  /s/ Larry Soll                   Director                )
  - ------------------------------                           )
  Larry Soll, Ph.D.                                        )
                                                           )
                                                           )
                                                           )
  
                                        -7-
  8
  
                                    EXHIBIT INDEX
                                    -------------
  
  Exhibit
  Number       Description                                         
  - -------      -----------                                         
                                                                   
   4.1 *       By-Laws of the Registrant                           
                                                                   
   4.2 *       Specimen Certificate of Common Stock of             
               the Registrant                                      
                                                                   
   4.3 **      Rights Agreement, dated as of July 11, 1995,        
               between the Registrant and the First National       
               Bank of Boston, as Rights Agent.                    
                                                                   
   5           Opinion of Hale and Dorr                            
                                                                   
  23.1         Consent of Hale and Dorr (included in Exhibit 5)    
                                                                   
  23.2         Consent of Coopers & Lybrand L.L.P.                 
                                                                   
  24           Power of Attorney (included in the signature pages  
               of this Registration Statement)                     
  
       ------------------------------
       *    Incorporated herein by reference from the Registrant's Registration 
            Statement on Form S-1 (File No. 33-39592).
  
       **   Incorporated herein by reference from the Registrant's Current Report
            on Form 8-K dated July 11, 1995.  
  
                                         -8-